Back

Mapping Disease Transitions from Premalignant, Asymptomatic to Advanced Myeloma through Integrative Epigenomic and Transcriptional Analyses

Kurowska, A.; Bantan, A.; Shuwaikan, R.; Gomez-Echarte, N.; Cenzano, I.; Aguirre-Ruiz, P.; Miranda, E.; Garate, L.; Vilas-Zornoza, A.; San-Martin, P.; Larrayoz, M.; Ariceta, B.; Amundarain, A.; Soto-Ortiz, D.; Tsitsianopoulos, M.; Papantonis, A.; Calasanz, M. J.; Martin-Subero, J. I.; Lagani, V.; Tegner, J.; Martinez-Climent, J. A.; Hernaez, M.; Planell, N.; Agirre, X.; Prosper, F.; Gomez-Cabrero, D.

2026-06-08 cancer biology
10.64898/2026.06.03.729851 bioRxiv
Show abstract

AbstractMultiple myeloma (MM) evolves from asymptomatic precursor conditions through progressive genetic and epigenetic remodeling, yet the regulatory mechanisms driving the development toward more active stages of the disease remain poorly understood. Here, we integrated bulk-based paired chromatin accessibility and activation, and transcriptomic profiling across disease stages to map regulatory remodeling during myeloma development. We identified a progressive increase in chromatin accessibility; furthermore, this epigenetic reconfiguration is accompanied by a stage-dependent shift from promoter-centered regulation in precursor states toward enhancer-dominated transcriptional control in active MM. Motif enrichment and regulatory network analyses identified both established and previously underappreciated transcription factors (TFs), including members of the IRF, MEF2, and FOX families, associated with disease-stage-specific transcriptional programs. Among these, MEF2D and FOXK2 emerged as candidate regulators of pathways involved in cell survival and chemotaxis. Functional perturbation demonstrated that MEF2D depletion markedly impaired MM cell viability, whereas inhibition of either MEF2D or FOXK2 reduced chemotactic migration. Together, these findings provide a stage-resolved framework of epigenetic and transcriptional remodeling across myeloma development, revealing regulatory programs established in precursor conditions and progressively reinforced during disease evolution, while identifying candidate transcriptional dependencies with potential biological and therapeutic relevance.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

1
Nature Communications
5641 papers in training set
Top 13%
13.0%
2
Leukemia
42 papers in training set
Top 0.1%
9.7%
3
Molecular Cancer Research
49 papers in training set
Top 0.2%
4.9%
4
Blood
74 papers in training set
Top 0.4%
4.3%
5
Blood Cancer Journal
14 papers in training set
Top 0.1%
4.3%
6
HemaSphere
16 papers in training set
Top 0.1%
3.5%
7
Cell Death & Disease
21 papers in training set
Top 0.1%
2.8%
8
Scientific Reports
3612 papers in training set
Top 42%
2.5%
9
Oncogene
85 papers in training set
Top 0.8%
2.4%
10
Cell Communication and Signaling
51 papers in training set
Top 0.3%
2.4%
11
Clinical Epigenetics
60 papers in training set
Top 0.2%
2.4%
50% of probability mass above
12
Cell Reports
1498 papers in training set
Top 18%
1.9%
13
Journal of Clinical Investigation
179 papers in training set
Top 3%
1.9%
14
Genome Medicine
183 papers in training set
Top 2%
1.9%
15
Science Advances
1243 papers in training set
Top 19%
1.7%
16
JCI Insight
277 papers in training set
Top 4%
1.7%
17
Advanced Science
286 papers in training set
Top 5%
1.7%
18
Haematologica
25 papers in training set
Top 0.4%
1.5%
19
eLife
5828 papers in training set
Top 53%
1.4%
20
Communications Biology
993 papers in training set
Top 19%
1.3%
21
Cancer Research
130 papers in training set
Top 2%
1.3%
22
Cancer Research Communications
51 papers in training set
Top 1%
1.1%
23
Cell Reports Medicine
153 papers in training set
Top 3%
1.1%
24
Clinical Cancer Research
64 papers in training set
Top 1%
1.1%
25
Blood Advances
62 papers in training set
Top 1.0%
1.0%
26
Acta Neuropathologica Communications
89 papers in training set
Top 2%
1.0%
27
Journal of Experimental Medicine
119 papers in training set
Top 3%
1.0%
28
Cells
249 papers in training set
Top 7%
0.8%
29
Cell Death Discovery
58 papers in training set
Top 1%
0.8%
30
Frontiers in Immunology
638 papers in training set
Top 9%
0.8%